Impact of Combined Prebiotic Galacto-Oligosaccharides and Bifidobacterium breve-Derived Postbiotic on Gut Microbiota and HbA1c in Prediabetic Adults: A Double-Blind, Randomized, Placebo-Controlled Study

Impact of Combined Prebiotic Galacto-Oligosaccharides and Bifidobacterium breve-Derived Postbiotic on Gut Microbiota and HbA1c in Prediabetic Adults: A Double-Blind, Randomized, Placebo-Controlled Study

ABSTRACT

The study examined the effects of a 12-week dietary fiber supplement on gut health and metabolic function in prediabetic adults. The supplement contained konjac glucomannan (KGM), galacto-oligosaccharides (GOSs), and exopolysaccharides (EPSs) from Bifidobacterium breve. In a randomized, double-blind, placebo-controlled clinical trial, 53 prediabetic volunteers were assigned to either the supplement or a placebo for 12 weeks, followed by a 4-week follow-up. The intervention group showed improvements in gut microbiota composition, glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and other health markers, while no significant changes were observed in the placebo group. The study suggests that dietary interventions targeting the human gut microbiome could be a promising approach to managing prediabetes and preventing or delaying diabetes.

Clinical Trials and Practical Solutions

Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, extending the benefits of clinical trials into everyday medical practice.

Value in Healthcare Operations

In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routines.

Learn more about how we can help at aidevmd.com.